Literature DB >> 33446229

Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival?

Andreas Selberherr1, Simon Freermann2, Oskar Koperek3, Martin B Niederle4, Philipp Riss2, Christian Scheuba2, Bruno Niederle2.   

Abstract

BACKGROUND: Neuroendocrine neoplasia of the small intestine (siNEN) are frequently diagnosed with liver metastases. The impact of the presence of liver metastases on overall survival and the necessity of surgery for liver metastasis is discussed controversially. The aim of this study is to evaluate and compare the overall long-term survival of patients with siNENs with and without liver metastasis at initial diagnosis and the possible benefit of surgical treatment as compared to active surveillance of metastases. 123 consecutive patients with siNENs were treated between 1965 and 2016. All clinical and histological records were reevaluated including analysis of the proliferation rates in all specimens. The 1-, 5-, 10- and 20-year overall survival was estimated by Kaplan-Meier analysis for patients with and without liver metastasis and according to the type of treatment (surgical vs. surveillance) of liver metastases if present.
RESULTS: The 1-, 5-, 10- and 20-year overall survival rate was 89.0%, 68.4%, 52.8% and 31.0% in patients without and 89.5%, 69.5%, 33.2% and 3.6% in those with liver metastases. No statistically significant differences were observed comparing the two groups. Within the group of patients with liver metastases, the type of treatment (surgical vs. surveillance) was in favor of patients undergoing surgery. Multivariate analysis showed that the presence of liver metastases upon diagnosis was an individual risk factor associated with worse survival.
CONCLUSION: The presence of liver metastasis at initial diagnosis does not have a statistically significant influence on survival. Surgery for hepatic metastasis seems to show a benefit for overall survival and may be indicated especially in patients symptomatic due to high tumor burden and serotonin hypersecretion to reduce hormone activity.

Entities:  

Keywords:  Livermetastasis; NEN; NET; Neuroendocrine neoplasia; Neuroendocrine tumors; Small intestine

Mesh:

Year:  2021        PMID: 33446229      PMCID: PMC7809808          DOI: 10.1186/s13023-021-01677-9

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  23 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents.

Authors:  Marianne Pavel; Juan W Valle; Barbro Eriksson; Anja Rinke; Martyn Caplin; Jie Chen; Frederico Costa; Jenny Falkerby; Nicola Fazio; Vera Gorbounova; Wouter de Herder; Matthew Kulke; Catherine Lombard-Bohas; J O'Connor; Halfdan Sorbye; Rocio Garcia-Carbonero
Journal:  Neuroendocrinology       Date:  2017-03-29       Impact factor: 4.914

3.  ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation.

Authors:  U Knigge; J Capdevila; D K Bartsch; E Baudin; J Falkerby; R Kianmanesh; B Kos-Kudla; B Niederle; E Nieveen van Dijkum; D O'Toole; A Pascher; N Reed; A Sundin; M-P Vullierme
Journal:  Neuroendocrinology       Date:  2017-02-17       Impact factor: 4.914

Review 4.  Surgical Treatment of Small Intestinal Neuroendocrine Tumors G1/G2.

Authors:  Andreas Selberherr; Martin B Niederle; Bruno Niederle
Journal:  Visc Med       Date:  2017-10-06

5.  Outcome of surgery for ileojejunal neuroendocrine tumors.

Authors:  Nils Habbe; Volker Fendrich; Anna Heverhagen; Annette Ramaswamy; Detlef K Bartsch
Journal:  Surg Today       Date:  2012-11-11       Impact factor: 2.549

Review 6.  Update on Surgical Management of Small Bowel Neuroendocrine Tumors.

Authors:  Demetrios Moris; Ioannis Ntanasis-Stathopoulos; Diamantis I Tsilimigras; Stylianos Vagios; Andreas Karamitros; Georgios Karaolanis; John Griniatsos; Alexandros Papalampros; Ioannis Papaconstantinou; Georgios K Glantzounis; Eleftherios Spartalis; Dan G Blazer; Evangelos Felekouras
Journal:  Anticancer Res       Date:  2018-03       Impact factor: 2.480

7.  The epidemiology of metastases in neuroendocrine tumors.

Authors:  Matias Riihimäki; Akseli Hemminki; Kristina Sundquist; Jan Sundquist; Kari Hemminki
Journal:  Int J Cancer       Date:  2016-09-09       Impact factor: 7.396

Review 8.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

9.  Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

Authors:  Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Edda Gomez-Panzani; Philippe Ruszniewski
Journal:  Endocr Relat Cancer       Date:  2016-01-07       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.